ALLR — Allarity Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$1.40
-$0.02 (-1.41%)
Allarity Therapeutics Inc (ALLR) is a biotechnology company listed on NASDAQ. It is led by Thomas H. Jensen, based in 24 School Street, Boston, MA, United States, 02108, with about 6 employees. Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Net income was -$2.8M. ALLR currently screens at market cap $15.1M and trailing P/E 0.0.
Use this ALLR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ALLR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ALLR SEC filings page. Lician reads the product cache first so this HTML stays unique to Allarity Therapeutics Inc even when a live quote feed is slow.
About Allarity Therapeutics Inc
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
ALLR Key Statistics
Market Cap
$15.08M
Volume
1,414
Previous Close
$1.39
Day Range
$1.38 – $1.38
P/E Ratio
0.00
EPS
$0.00
Revenue
$0.00
Net Income
-$24.52M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
6
ALLR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$24.52M | -$11.90M | -$16.06M | -$26.65M |
| EPS (Diluted) | $0.00 | -$10.26 | -$3.09K | -$4.19 |
Total Assets
$22.65M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$19.53M
Operating Cash Flow
-$17.35M
Free Cash Flow
$0.00
Allarity Therapeutics Inc Company Information
- Founder, CEO & Director
- Thomas H. Jensen
- Headquarters
- 24 School Street, Boston, MA, United States, 02108
- Website
- www.allarity.com
- Phone
- 401 426 4664
- IPO / Founded
- 2021-12-21
- Sector
- Healthcare
- Industry
- Biotechnology